{"fetched":"2026-10-29","congress":{"id":"esmo","label":"ESMO Congress","year":2026,"journal":"Annals of Oncology","window":{"from":"2026-09-01","to":"2026-11-15"},"source":"https://api.crossref.org/"},"total":466,"considered":216,"matched":114,"items":[{"doi":"10.1016/j.annonc.2026.09.002","url":"https://doi.org/10.1016/j.annonc.2026.09.002","title":"Safety and antitumor activity of the first-in-class EGFR–HER3 bispecific antibody–drug conjugate iza-bren (BL-B01D1) in patients with pretreated locally advanced or metastatic breast cancer: a phase Ib study","date":"2026-09-01","lba":false,"refs":{"drugs":["mcla-129","izalontamab-brengitecan"],"trials":["nct06561607","nct07678957","nct06202261","nct07497386","nct07558733","nct06702618","nct06957886","nct06308406","nct07040228","nct07358585","nct07750041","nct07621159","nct07361003","nct05846867","nct07226986","nct06848699","nct05910827","nct05229497","nct07501559","nct06474455","nct07002177","nct07547553","nct05951608","nct07466160","nct07283367","nct05543330","nct05035745","nct07342725","nct06454448","nct07353268","nct05503888","nct07239596","nct05024214","nct07590934","nct03260023","nct06590246","nct07235176","nct05720130","nct07617805"],"targets":["her3","egfr"],"cancers":["breast-cancer"],"technologies":["adc"]}},{"doi":"10.1016/j.annonc.2026.07.215","url":"https://doi.org/10.1016/j.annonc.2026.07.215","title":"P004-10 Relapsed and refractory multiple myeloma treated with elranatamab in our hospital","date":"2026-11-01","lba":false,"refs":{"drugs":["elranatamab"],"trials":["nct05862012","nct06413498","nct06235229","nct07284758","nct06566547","nct06115135","nct07455851","nct06668792","nct05850234","nct07454187","nct04162210","nct04126200","nct01827605","nct05947851"],"targets":[],"cancers":["multiple-myeloma"],"technologies":[]}},{"doi":"10.1016/j.annonc.2026.07.217","url":"https://doi.org/10.1016/j.annonc.2026.07.217","title":"P004-6 The results of anti-BCMA/CD3 bispecific antibodies therapy for triple-class exposed relapsed/refractory multiple myeloma","date":"2026-11-01","lba":false,"refs":{"drugs":["mcla-129"],"trials":["nct05862012","nct06413498","nct06235229","nct07284758","nct06566547","nct06115135","nct07455851","nct06668792","nct05850234","nct07454187","nct04162210","nct04126200","nct01827605","nct05947851"],"targets":["bcma"],"cancers":["multiple-myeloma"],"technologies":["bispecific-antibody"]}},{"doi":"10.1016/j.annonc.2026.07.322","url":"https://doi.org/10.1016/j.annonc.2026.07.322","title":"P073-1 Capivasertib access via CGP after CDK4/6i in HR+/HER2- metastatic breast cancer: a retrospective single-center study","date":"2026-11-01","lba":false,"refs":{"drugs":["capivasertib"],"trials":["nct06428396","nct04639986","nct06561607","nct07678957","nct06202261","nct07497386","nct07558733","nct06702618","nct06957886","nct04862663","nct06790693"],"targets":["her2","cdk4-6"],"cancers":["breast-cancer"],"technologies":["cdk46-inhibitor"]}},{"doi":"10.1016/j.annonc.2026.07.385","url":"https://doi.org/10.1016/j.annonc.2026.07.385","title":"P113-3 Prognostic significance of number of liver metastases in advanced pancreatic cancer on Nab-paclitaxel plus gemcitabine","date":"2026-11-01","lba":false,"refs":{"drugs":["gemcitabine-nab-paclitaxel","nab-paclitaxel","paclitaxel","gemcitabine-cisplatin","gemcitabine"],"trials":["nct07353645","nct07103447","nct05582538","nct04605913","nct05035745","nct06590246"],"targets":[],"cancers":["metastatic-pdac","pancreatic"],"technologies":[]}},{"doi":"10.1016/j.annonc.2026.07.280","url":"https://doi.org/10.1016/j.annonc.2026.07.280","title":"P045-3 From hyperprogression to hope: salvage Nab-paclitaxel in recurrent oropharyngeal cancer on pembrolizumab","date":"2026-11-01","lba":false,"refs":{"drugs":["gemcitabine-nab-paclitaxel","nab-paclitaxel","paclitaxel","pembrolizumab"],"trials":["nct07103447","nct05582538","nct04605913","nct06976944","nct04153734","nct05224141"],"targets":[],"cancers":["oropharyngeal-cancer"],"technologies":[]}},{"doi":"10.1016/j.annonc.2026.09.005","url":"https://doi.org/10.1016/j.annonc.2026.09.005","title":"Navigating uncertainties and evidence gaps in adjuvant therapy for premenopausal women with HR+/HER2- breast cancer","date":"2026-09-01","lba":false,"refs":{"drugs":[],"trials":["nct07461454","nct06383767","nct06982521","nct06081959","nct05501886","nct05455619","nct04862663","nct05607004","nct04851613"],"targets":["her2"],"cancers":["breast-cancer"],"technologies":[]}},{"doi":"10.1016/j.annonc.2026.07.268","url":"https://doi.org/10.1016/j.annonc.2026.07.268","title":"P035-6 Efficacy on the use of co-injected dexamethasone for oxaliplatin-induced vascular pain in CapeOX ± bevacizumab therapy","date":"2026-11-01","lba":false,"refs":{"drugs":["dexamethasone","bevacizumab-glioma","bevacizumab","oxaliplatin"],"trials":["nct06782685","nct06791512","nct07007767","nct05281471","nct06463665"],"targets":[],"cancers":[],"technologies":[]}},{"doi":"10.1016/j.annonc.2026.07.308","url":"https://doi.org/10.1016/j.annonc.2026.07.308","title":"P066-11 Effective treatment of leptomeningeal carcinomatosis with erlotinib and bevacizumab in two cases of EGFR-mutant NSCLC","date":"2026-11-01","lba":false,"refs":{"drugs":["bevacizumab-glioma","bevacizumab","erlotinib"],"trials":["nct06791512","nct07007767","nct06745882","nct07728955","nct06441344","nct07617805"],"targets":["egfr"],"cancers":["nsclc"],"technologies":[]}},{"doi":"10.1016/j.annonc.2026.07.357","url":"https://doi.org/10.1016/j.annonc.2026.07.357","title":"P098-11 Assessing efficacy and safety of pembrolizumab combined with chemoradiation in NSCLC: a systematic review","date":"2026-11-01","lba":false,"refs":{"drugs":["pembrolizumab"],"trials":["nct06976944","nct04153734","nct05224141","nct05281471","nct06463665","nct06745882","nct07728955","nct06441344"],"targets":[],"cancers":["nsclc"],"technologies":[]}},{"doi":"10.1016/j.annonc.2026.09.011","url":"https://doi.org/10.1016/j.annonc.2026.09.011","title":"Final results and predictive biomarkers of response and long-term outcomes with first-line pembrolizumab monotherapy in advanced renal cell carcinoma in the phase II KEYNOTE-427 study","date":"2026-09-01","lba":false,"refs":{"drugs":["pembrolizumab"],"trials":["nct06976944","nct04153734","nct05224141","nct05035745","nct05744687","nct06590246","nct07290088"],"targets":[],"cancers":["rcc"],"technologies":[]}},{"doi":"10.1016/j.annonc.2026.09.009","url":"https://doi.org/10.1016/j.annonc.2026.09.009","title":"Final results of nivolumab plus ipilimumab versus nivolumab or chemotherapy in microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer from CheckMate 8HW","date":"2026-10-01","lba":false,"refs":{"drugs":["ipilimumab","nivolumab","relatlimab-nivolumab"],"trials":["nct07535632","nct06992258","checkmate-8hw","nct07381309","nct05663775"],"targets":["mmr"],"cancers":["colorectal"],"technologies":[]}},{"doi":"10.1016/j.annonc.2026.07.219","url":"https://doi.org/10.1016/j.annonc.2026.07.219","title":"P008-3 Early- vs late-line eribulin in metastatic breast cancer: a target trial emulation with propensity score modeling","date":"2026-11-01","lba":false,"refs":{"drugs":["eribulin"],"trials":["nct06561607","nct07678957","nct06202261","nct07497386","nct07558733","nct06702618","nct06957886"],"targets":[],"cancers":["breast-cancer"],"technologies":[]}},{"doi":"10.1016/j.annonc.2026.07.243","url":"https://doi.org/10.1016/j.annonc.2026.07.243","title":"P022-5 Efficacy of lenvatinib, ifosfamide and etoposide for relapsed osteosarcoma: a systematic review","date":"2026-11-01","lba":false,"refs":{"drugs":["lenvatinib","ifosfamide","platinum-etoposide","etoposide"],"trials":["nct04875585","nct05281471","nct06463665","nct05947851"],"targets":[],"cancers":["osteosarcoma"],"technologies":[]}},{"doi":"10.1016/j.annonc.2026.07.297","url":"https://doi.org/10.1016/j.annonc.2026.07.297","title":"P057-4 Safety and efficacy of pertuzumab and trastuzumab in HER2-positive metastatic colorectal cancer: comparison of IV and SC","date":"2026-11-01","lba":false,"refs":{"drugs":["trastuzumab","pertuzumab"],"trials":["nct07535632","nct06992258","nct06891833","nct04514419","nct05281471","nct06463665"],"targets":["her2"],"cancers":["colorectal"],"technologies":[]}},{"doi":"10.1016/j.annonc.2026.07.298","url":"https://doi.org/10.1016/j.annonc.2026.07.298","title":"P058-3 Efficacy of immune checkpoint inhibitors in dMMR vs pMMR metastatic colorectal cancer: a meta-analysis of RCTs","date":"2026-11-01","lba":false,"refs":{"drugs":[],"trials":["nct07021950","nct06685276","nct07535632","nct06154538","nct06992258","nct05281471","nct06463665","nct07651007"],"targets":[],"cancers":["colorectal"],"technologies":["checkpoint-inhibitor"]}},{"doi":"10.1016/j.annonc.2026.07.315","url":"https://doi.org/10.1016/j.annonc.2026.07.315","title":"P070-3 Neoadjuvant chemotherapy with pembrolizumab in stage II-III TNBC at Ho Chi Minh City Oncology Hospital","date":"2026-11-01","lba":false,"refs":{"drugs":["pembrolizumab"],"trials":["nct06976944","nct04153734","nct05224141","nct07381309","nct05562297","nct07412613","nct03168880"],"targets":[],"cancers":[],"technologies":[]}},{"doi":"10.1016/j.annonc.2026.07.358","url":"https://doi.org/10.1016/j.annonc.2026.07.358","title":"P098-12 Nivolumab in advanced NSCLC as first-line combination vs. second-line monotherapy: systematic review and meta-analysis","date":"2026-11-01","lba":false,"refs":{"drugs":["nivolumab","relatlimab-nivolumab"],"trials":["nct05663775","nct05035745","nct06590246","nct06745882","nct07728955","nct06441344"],"targets":[],"cancers":["nsclc"],"technologies":[]}},{"doi":"10.1016/j.annonc.2026.07.376","url":"https://doi.org/10.1016/j.annonc.2026.07.376","title":"P109-9 Assessing efficacy and safety of lenvatinib combined with pembrolizumab in hepatocellular carcinoma: a systematic review","date":"2026-11-01","lba":false,"refs":{"drugs":["pembrolizumab","lenvatinib"],"trials":["nct06976944","nct04153734","nct05224141","nct04875585","nct05281471","nct06463665"],"targets":[],"cancers":["hcc"],"technologies":[]}},{"doi":"10.1016/j.annonc.2026.07.380","url":"https://doi.org/10.1016/j.annonc.2026.07.380","title":"P112-3 Efficacy of chemotherapy after nanoliposomal irinotecan/fluorouracil/folinic acid for unresectable pancreatic cancer","date":"2026-11-01","lba":false,"refs":{"drugs":["leucovorin","fluorouracil","irinotecan"],"trials":["nct07539155","nct07353645","nct07381309","nct05281471","nct06463665"],"targets":["psmd1"],"cancers":["pancreatic"],"technologies":[]}},{"doi":"10.1016/j.annonc.2026.07.388","url":"https://doi.org/10.1016/j.annonc.2026.07.388","title":"P114-6 Clinical experience with pembrolizumab plus lenvatinib combination therapy for advanced renal cell carcinoma","date":"2026-11-01","lba":false,"refs":{"drugs":["pembrolizumab","lenvatinib"],"trials":["nct06976944","nct04153734","nct05224141","nct04875585","nct05035745","nct06590246"],"targets":[],"cancers":["rcc"],"technologies":[]}},{"doi":"10.1016/j.annonc.2026.07.258","url":"https://doi.org/10.1016/j.annonc.2026.07.258","title":"P031-9 Efficacy and safety of gemcitabine plus cisplatin for nasopharyngeal carcinoma: a retrospective analysis of five cases","date":"2026-11-01","lba":false,"refs":{"drugs":["gemcitabine-nab-paclitaxel","gemcitabine-cisplatin","gemcitabine","cisplatin"],"trials":["nct04605913","nct05281471","nct06463665"],"targets":[],"cancers":["nasopharyngeal"],"technologies":[]}},{"doi":"10.1016/j.annonc.2026.07.260","url":"https://doi.org/10.1016/j.annonc.2026.07.260","title":"P032-7 Gemcitabine/cisplatin versus cisplatin/fluorouracil as induction chemotherapy in stage III-Iva nasopharyngeal carcinoma","date":"2026-11-01","lba":false,"refs":{"drugs":["fluorouracil","gemcitabine-nab-paclitaxel","gemcitabine-cisplatin","gemcitabine","cisplatin"],"trials":["nct07381309","nct04605913"],"targets":[],"cancers":["nasopharyngeal"],"technologies":[]}},{"doi":"10.1016/j.annonc.2026.07.275","url":"https://doi.org/10.1016/j.annonc.2026.07.275","title":"P040-5 Telisotuzumab adizutecan (Temab-A) plus osimertinib (osi) as 1L treatment for unresectable/metastatic NSCLC","date":"2026-11-01","lba":false,"refs":{"drugs":["telisotuzumab-adizutecan","osimertinib"],"trials":["nct05859217","nct06908304","nct06745882","nct07728955","nct06441344"],"targets":[],"cancers":["nsclc"],"technologies":[]}},{"doi":"10.1016/j.annonc.2026.07.303","url":"https://doi.org/10.1016/j.annonc.2026.07.303","title":"P064-5 Efficacy of neoadjuvant immunotherapy in resectable NSCLC: a systematic review","date":"2026-11-01","lba":false,"refs":{"drugs":[],"trials":["nct05562297","nct07412613","nct05281471","nct06463665","nct06745882","nct07728955","nct06441344"],"targets":[],"cancers":["nsclc"],"technologies":[]}},{"doi":"10.1016/j.annonc.2026.07.318","url":"https://doi.org/10.1016/j.annonc.2026.07.318","title":"P072-1 Profile and outcomes of PIK3CA and ESR1 mutated hormone receptor-positive metastatic breast cancer: an Indian context","date":"2026-11-01","lba":false,"refs":{"drugs":[],"trials":["nct06561607","nct07678957","nct06202261","nct07497386","nct07558733","nct06702618","nct06957886"],"targets":["pik3ca"],"cancers":["breast-cancer"],"technologies":[]}},{"doi":"10.1016/j.annonc.2026.07.321","url":"https://doi.org/10.1016/j.annonc.2026.07.321","title":"P072-8 Unusual response to endocrine therapy in metastatic breast cancer","date":"2026-11-01","lba":false,"refs":{"drugs":[],"trials":["nct06561607","nct07678957","nct06202261","nct07497386","nct07558733","nct06702618","nct06957886"],"targets":[],"cancers":["breast-cancer"],"technologies":["endocrine-therapy"]}},{"doi":"10.1016/j.annonc.2026.07.274","url":"https://doi.org/10.1016/j.annonc.2026.07.274","title":"P040-3 FUSION: a randomized phase II study of fruquintinib in advanced salivary gland cancer utilizing a decentralized approach","date":"2026-11-01","lba":false,"refs":{"drugs":["fruquintinib"],"trials":["nct07353268","nct05035745","nct05744687","nct06590246","nct07290088"],"targets":[],"cancers":[],"technologies":[]}},{"doi":"10.1016/j.annonc.2026.07.282","url":"https://doi.org/10.1016/j.annonc.2026.07.282","title":"P047-1 Pembrolizumab plus trastuzumab as frontline therapy in HER2-positive gastric cancer: a systematic review","date":"2026-11-01","lba":false,"refs":{"drugs":["pembrolizumab","trastuzumab"],"trials":["nct06976944","nct04153734","nct05224141","nct06891833"],"targets":["her2"],"cancers":["gastric-her2-positive","gastric"],"technologies":[]}},{"doi":"10.1016/j.annonc.2026.07.306","url":"https://doi.org/10.1016/j.annonc.2026.07.306","title":"P066-1 CNS adverse events in patients with ALK+ advanced NSCLC treated with first-line lorlatinib in clinical settings in Japan","date":"2026-11-01","lba":false,"refs":{"drugs":["lorlatinib"],"trials":["nct05035745","nct06590246","nct06745882","nct07728955","nct06441344"],"targets":[],"cancers":["nsclc"],"technologies":[]}},{"doi":"10.1016/j.annonc.2026.07.310","url":"https://doi.org/10.1016/j.annonc.2026.07.310","title":"P067-3 Real world clinical outcomes among patients with aNSCLC treated with 1L pembrolizumab combination regimens in Japan","date":"2026-11-01","lba":false,"refs":{"drugs":["pembrolizumab"],"trials":["nct06976944","nct04153734","nct05224141","nct07728955","nct06441344"],"targets":[],"cancers":[],"technologies":[]}},{"doi":"10.1016/j.annonc.2026.07.311","url":"https://doi.org/10.1016/j.annonc.2026.07.311","title":"P067-5 Prognostic factors in advanced or recurrent NSCLC treated with ICI plus chemotherapy: retrospective study","date":"2026-11-01","lba":false,"refs":{"drugs":[],"trials":["nct07381309","nct05035745","nct06590246","nct06745882","nct07728955","nct06441344"],"targets":[],"cancers":["nsclc"],"technologies":[]}},{"doi":"10.1016/j.annonc.2026.07.331","url":"https://doi.org/10.1016/j.annonc.2026.07.331","title":"P078-6 Comprehensive genomic profiling in non-targetable advanced NSCLC patients","date":"2026-11-01","lba":false,"refs":{"drugs":[],"trials":["nct06922591","nct05035745","nct06590246","nct06745882","nct07728955","nct06441344"],"targets":[],"cancers":["nsclc"],"technologies":["cgp"]}},{"doi":"10.1016/j.annonc.2026.07.238","url":"https://doi.org/10.1016/j.annonc.2026.07.238","title":"P019-3 Efficacy and safety of sorafenib in advanced follicular thyroid carcinoma patient: a systematic review","date":"2026-11-01","lba":false,"refs":{"drugs":["sorafenib"],"trials":["nct05035745","nct05281471","nct06463665","nct06590246"],"targets":[],"cancers":["follicular-thyroid-cancer"],"technologies":[]}},{"doi":"10.1016/j.annonc.2026.07.240","url":"https://doi.org/10.1016/j.annonc.2026.07.240","title":"P020-7 Efficacy and safety of fecal microbiota transplantation with PD-1 therapy in advanced melanoma: a systematic review","date":"2026-11-01","lba":false,"refs":{"drugs":[],"trials":["nct05035745","nct05281471","nct06463665","nct06590246","nct07277842"],"targets":["pd1"],"cancers":["advanced-melanoma","melanoma"],"technologies":[]}},{"doi":"10.1016/j.annonc.2026.07.276","url":"https://doi.org/10.1016/j.annonc.2026.07.276","title":"P041-4 ONO-4538-131: phase II study of ONO-4538 (nivolumab) in patients with Richter's transformation","date":"2026-11-01","lba":false,"refs":{"drugs":["nivolumab","relatlimab-nivolumab"],"trials":["nct05663775","nct05744687","nct07290088"],"targets":["trrap"],"cancers":["richter-transformation-cll"],"technologies":[]}},{"doi":"10.1016/j.annonc.2026.07.283","url":"https://doi.org/10.1016/j.annonc.2026.07.283","title":"P047-3 Comparison of nivolumab-combined chemo versus EP/EC therapy in advanced gastric and gastroesophageal junction NEC","date":"2026-11-01","lba":false,"refs":{"drugs":["nivolumab","relatlimab-nivolumab"],"trials":["nct05663775","nct05035745","nct06590246"],"targets":[],"cancers":["gastric"],"technologies":[]}},{"doi":"10.1016/j.annonc.2026.07.309","url":"https://doi.org/10.1016/j.annonc.2026.07.309","title":"P067-2 Survivorship after 2-year immune checkpoint inhibitor therapy in advanced NSCLC: insight from Korean national claim data","date":"2026-11-01","lba":false,"refs":{"drugs":[],"trials":["nct05035745","nct06590246","nct06745882","nct07728955","nct06441344"],"targets":[],"cancers":["nsclc"],"technologies":[]}},{"doi":"10.1016/j.annonc.2026.07.324","url":"https://doi.org/10.1016/j.annonc.2026.07.324","title":"P073-8 Efficacy of fulvestrant as endocrine therapy in hormone receptor-positive advanced breast cancer","date":"2026-11-01","lba":false,"refs":{"drugs":["fulvestrant"],"trials":["nct05035745","nct05281471","nct06463665","nct06590246"],"targets":[],"cancers":["breast-cancer"],"technologies":["endocrine-therapy"]}},{"doi":"10.1016/j.annonc.2026.07.353","url":"https://doi.org/10.1016/j.annonc.2026.07.353","title":"P096-7 Concurrent use of imatinib and pembrolizumab in a patient with CML and lung adenocarcinoma: a case report","date":"2026-11-01","lba":false,"refs":{"drugs":["pembrolizumab","imatinib"],"trials":["nct06976944","nct04153734","nct05224141"],"targets":[],"cancers":["nsclc","lung-adenocarcinoma","urethral-adenocarcinoma"],"technologies":[]}},{"doi":"10.1016/j.annonc.2026.07.383","url":"https://doi.org/10.1016/j.annonc.2026.07.383","title":"P112-10 Intracellular pH regulation links FAM111B suppression to enhanced gemcitabine sensitivity in Pancreatic cancer","date":"2026-11-01","lba":false,"refs":{"drugs":["gemcitabine-nab-paclitaxel","gemcitabine-cisplatin","gemcitabine"],"trials":["nct07353645","nct04605913"],"targets":["psmd1"],"cancers":["pancreatic"],"technologies":[]}},{"doi":"10.1016/j.annonc.2026.07.382","url":"https://doi.org/10.1016/j.annonc.2026.07.382","title":"P112-9 Retrospective analysis of nanoliposomal irinotecan plus 5-FU/LV in patients with advanced pancreatic adenocarcinoma","date":"2026-11-01","lba":false,"refs":{"drugs":["irinotecan"],"trials":["nct05035745","nct06590246","nct06662006","nct06782685"],"targets":["psmd1"],"cancers":["pancreatic","urethral-adenocarcinoma","lung-adenocarcinoma"],"technologies":[]}},{"doi":"10.1016/j.annonc.2026.09.016","url":"https://doi.org/10.1016/j.annonc.2026.09.016","title":"Postoperative ctDNA dynamics and eligibility for Treat-on-Molecular Result (TOMR) ALTAIR trial in colorectal cancer: insights from CIRCULATE-Japan","date":"2026-10-01","lba":false,"refs":{"drugs":[],"trials":["circulate-japan","nct04120701","altair","nct06996782","alta"],"targets":[],"cancers":["colorectal"],"technologies":[]}},{"doi":"10.1016/j.annonc.2026.07.228","url":"https://doi.org/10.1016/j.annonc.2026.07.228","title":"P016-3 Safety and efficacy of alpelisib in metastatic PIK3CA-mutated breast carcinoma: preliminary real world Indian experience","date":"2026-11-01","lba":false,"refs":{"drugs":["alpelisib"],"trials":["nct05660083","nct05281471","nct06463665"],"targets":["pik3ca"],"cancers":["breast-cancer"],"technologies":[]}},{"doi":"10.1016/j.annonc.2026.07.229","url":"https://doi.org/10.1016/j.annonc.2026.07.229","title":"P016-6 Efficacy and safety of sacituzumab govitecan in Indian patients with metastatic triple-negative breast cancer","date":"2026-11-01","lba":false,"refs":{"drugs":["sacituzumab-govitecan"],"trials":["nct06767527","nct05281471","nct06463665"],"targets":[],"cancers":["tnbc-metastatic","tnbc","breast-cancer"],"technologies":[]}},{"doi":"10.1016/j.annonc.2026.07.286","url":"https://doi.org/10.1016/j.annonc.2026.07.286","title":"P050-7 Two cases of conversion surgery following zolbetuximab-based chemotherapy for advanced gastric cancer","date":"2026-11-01","lba":false,"refs":{"drugs":["zolbetuximab"],"trials":["nct07381309","nct05035745","nct06590246"],"targets":[],"cancers":["gastric"],"technologies":[]}},{"doi":"10.1016/j.annonc.2026.07.293","url":"https://doi.org/10.1016/j.annonc.2026.07.293","title":"P055-1 Trastuzumab-deruxtecan leads the ADC era in metastatic colorectal cancer: evidence from a comprehensive meta-analysis","date":"2026-11-01","lba":false,"refs":{"drugs":["trastuzumab"],"trials":["nct07535632","nct06992258","nct06891833"],"targets":[],"cancers":["colorectal"],"technologies":[]}},{"doi":"10.1016/j.annonc.2026.07.305","url":"https://doi.org/10.1016/j.annonc.2026.07.305","title":"P065-3 Phase II study of necitumumab + chemotherapy in lung squamous cell carcinoma: exploratory analysis of WJOG14120L NESSIE","date":"2026-11-01","lba":false,"refs":{"drugs":["necitumumab"],"trials":["nct07381309","nct05744687","nct07290088"],"targets":[],"cancers":["nsclc","lung-squamous-cell-carcinoma","urethral-squamous-cell-carcinoma"],"technologies":[]}},{"doi":"10.1016/j.annonc.2026.07.307","url":"https://doi.org/10.1016/j.annonc.2026.07.307","title":"P066-4 Central nervous system adverse events and tolerability of lorlatinib in ALK fusion-positive NSCLC in clinical practice","date":"2026-11-01","lba":false,"refs":{"drugs":["lorlatinib"],"trials":["nct06745882","nct07728955","nct06441344"],"targets":[],"cancers":["nsclc"],"technologies":[]}},{"doi":"10.1016/j.annonc.2026.07.319","url":"https://doi.org/10.1016/j.annonc.2026.07.319","title":"P072-3 Predictive factors to CDK4/6 inhibitors used in advanced breast cancer","date":"2026-11-01","lba":false,"refs":{"drugs":[],"trials":["nct05035745","nct06590246","nct04862663","nct06790693"],"targets":["cdk4-6"],"cancers":["breast-cancer","hr-positive-metastatic-post-cdk46"],"technologies":["cdk46-inhibitor"]}},{"doi":"10.1016/j.annonc.2026.07.339","url":"https://doi.org/10.1016/j.annonc.2026.07.339","title":"P086-9 Resveratrol as a natural adjuvant to protect muscle atrophy from cisplatin-induced ferroptosis","date":"2026-11-01","lba":false,"refs":{"drugs":["gemcitabine-cisplatin","cisplatin"],"trials":["nct04605913","protect"],"targets":[],"cancers":[],"technologies":[]}},{"doi":"10.1016/j.annonc.2026.07.359","url":"https://doi.org/10.1016/j.annonc.2026.07.359","title":"P100-2 SMARCA4 is enriched in younger patients and linked to inferior ICI outcomes in driver-negative NSCLC: C-CAT analysis","date":"2026-11-01","lba":false,"refs":{"drugs":[],"trials":["nct07551635","nct06745882","nct07728955","nct06441344"],"targets":["smarca4","snd1","nfkb2"],"cancers":["nsclc"],"technologies":[]}},{"doi":"10.1016/j.annonc.2026.07.212","url":"https://doi.org/10.1016/j.annonc.2026.07.212","title":"P002-5 Overcoming antigen escape in diffuse large B-cell lymphoma: a meta-analysis of dual-target CAR T-cell therapy","date":"2026-11-01","lba":false,"refs":{"drugs":[],"trials":["nct05487170","jcog9801","nct07075328"],"targets":["bcl10","bcl11b"],"cancers":["dlbcl","high-grade-b-cell-lymphoma-myc-bcl2","non-hodgkin-lymphoma","adult-t-cell-leukaemia-lymphoma","t-cell-histiocyte-rich-large-b-cell-lymphoma"],"technologies":["car-t"]}},{"doi":"10.1016/j.annonc.2026.07.214","url":"https://doi.org/10.1016/j.annonc.2026.07.214","title":"P003-8 Real-world efficacy and safety of CPX-351 in high-risk acute myeloid leukemia","date":"2026-11-01","lba":false,"refs":{"drugs":["cpx-351"],"trials":["nct05281471","nct06463665"],"targets":[],"cancers":["leukaemia"],"technologies":[]}},{"doi":"10.1016/j.annonc.2026.07.221","url":"https://doi.org/10.1016/j.annonc.2026.07.221","title":"P010-1 Efficacy of PI3K inhibitors in hormone receptor-positive breast cancer: a meta-analysis of progression-free survival","date":"2026-11-01","lba":false,"refs":{"drugs":[],"trials":["nct05281471","nct06463665","nct07109726"],"targets":[],"cancers":["breast-cancer"],"technologies":[]}},{"doi":"10.1016/j.annonc.2026.07.235","url":"https://doi.org/10.1016/j.annonc.2026.07.235","title":"P018-8 Assessing the safety and efficacy of ONC201 in glioma: a systematic review of clinical outcomes","date":"2026-11-01","lba":false,"refs":{"drugs":["dordaviprone"],"trials":["nct05281471","nct06463665"],"targets":[],"cancers":["glioblastoma"],"technologies":[]}},{"doi":"10.1016/j.annonc.2026.07.241","url":"https://doi.org/10.1016/j.annonc.2026.07.241","title":"P020-9 Comparative efficacy of BRAF/MEK and immune checkpoint inhibitors in BRAF-mutant melanoma: a systematic review","date":"2026-11-01","lba":false,"refs":{"drugs":[],"trials":["nct06154538","nct05281471","nct06463665"],"targets":["braf"],"cancers":["braf-v600-melanoma","melanoma"],"technologies":["checkpoint-inhibitor"]}},{"doi":"10.1016/j.annonc.2026.07.270","url":"https://doi.org/10.1016/j.annonc.2026.07.270","title":"P036-4 Role of ketamine as an adjuvant for refractory cancer pain: a systematic review of analgesic efficacy and safety","date":"2026-11-01","lba":false,"refs":{"drugs":[],"trials":["nct01827605","nct05281471","nct06463665"],"targets":[],"cancers":[],"technologies":[]}},{"doi":"10.1016/j.annonc.2026.07.271","url":"https://doi.org/10.1016/j.annonc.2026.07.271","title":"P036-8 Development of a prediction model for capecitabine-induced hand-foot syndrome","date":"2026-11-01","lba":false,"refs":{"drugs":["capecitabine-temozolomide","capecitabine"],"trials":["nct07281768"],"targets":[],"cancers":[],"technologies":[]}},{"doi":"10.1016/j.annonc.2026.07.285","url":"https://doi.org/10.1016/j.annonc.2026.07.285","title":"P050-5 Real-world experience of zolbetuximab for CLDN18.2-positive advanced gastric cancer in Saga","date":"2026-11-01","lba":false,"refs":{"drugs":["zolbetuximab"],"trials":["nct05035745","nct06590246"],"targets":[],"cancers":["gastric"],"technologies":[]}},{"doi":"10.1016/j.annonc.2026.07.304","url":"https://doi.org/10.1016/j.annonc.2026.07.304","title":"P065-2 Real-world treatment patterns and duration in Japanese patients with NSCLC: a retrospective claims database study","date":"2026-11-01","lba":false,"refs":{"drugs":[],"trials":["nct06745882","nct07728955","nct06441344"],"targets":[],"cancers":["nsclc"],"technologies":[]}},{"doi":"10.1016/j.annonc.2026.07.316","url":"https://doi.org/10.1016/j.annonc.2026.07.316","title":"P071-2 Efficacy of AURORA B kinase inhibitors in breast cancer patients is dependent on mitotic checkpoint regulators","date":"2026-11-01","lba":false,"refs":{"drugs":[],"trials":["nct05281471","nct06463665","aurora"],"targets":[],"cancers":["breast-cancer"],"technologies":[]}},{"doi":"10.1016/j.annonc.2026.07.323","url":"https://doi.org/10.1016/j.annonc.2026.07.323","title":"P073-6 Efficacy of immune checkpoint inhibitors in triple-negative breast cancer: a systematic review","date":"2026-11-01","lba":false,"refs":{"drugs":[],"trials":["nct06154538","nct05281471","nct06463665"],"targets":[],"cancers":["tnbc","breast-cancer"],"technologies":["checkpoint-inhibitor"]}},{"doi":"10.1016/j.annonc.2026.07.328","url":"https://doi.org/10.1016/j.annonc.2026.07.328","title":"P077-3 Modeling the pre-test ctDNA detectability in liquid CGP for advanced pancreatic cancer","date":"2026-11-01","lba":false,"refs":{"drugs":[],"trials":["nct07353645","nct05035745","nct06590246"],"targets":[],"cancers":["metastatic-pdac","pancreatic"],"technologies":[]}},{"doi":"10.1016/j.annonc.2026.07.355","url":"https://doi.org/10.1016/j.annonc.2026.07.355","title":"P097-7 Polatuzumab vedotin as second-line therapy for recurrent primary cutaneous B-cell lymphoma in an elderly: a case report","date":"2026-11-01","lba":false,"refs":{"drugs":["polatuzumab-vedotin"],"trials":["jcog9801","nct07075328"],"targets":["bcl10","bcl11b"],"cancers":["non-hodgkin-lymphoma","adult-t-cell-leukaemia-lymphoma"],"technologies":[]}},{"doi":"10.1016/j.annonc.2026.07.356","url":"https://doi.org/10.1016/j.annonc.2026.07.356","title":"P097-9 Richter transformation of CLL to diffuse large B-cell lymphoma: a case report and review of literature","date":"2026-11-01","lba":false,"refs":{"drugs":[],"trials":["nct05487170","jcog9801","nct07075328"],"targets":["bcl10","bcl11b","trrap"],"cancers":["dlbcl","high-grade-b-cell-lymphoma-myc-bcl2","non-hodgkin-lymphoma","adult-t-cell-leukaemia-lymphoma"],"technologies":[]}},{"doi":"10.1016/j.annonc.2026.07.360","url":"https://doi.org/10.1016/j.annonc.2026.07.360","title":"P100-3 Co-mutations modulate ICI benefit and survival in KEAP1/NRF2-altered NSCLC: a nationwide C-CAT cohort analysis","date":"2026-11-01","lba":false,"refs":{"drugs":[],"trials":["nct06745882","nct07728955","nct06441344"],"targets":["keap1","nfe2l2","snd1","nfkb2"],"cancers":["nsclc"],"technologies":[]}},{"doi":"10.1016/j.annonc.2026.07.361","url":"https://doi.org/10.1016/j.annonc.2026.07.361","title":"P100-6 Adagrasib in KRAS G12C-mutated non-small cell lung cancer: a systematic review","date":"2026-11-01","lba":false,"refs":{"drugs":["adagrasib"],"trials":["nct05318573","nct06248606"],"targets":["kras","snd1","nfkb2"],"cancers":["lung-cancer"],"technologies":["kras-inhibitors"]}},{"doi":"10.1016/j.annonc.2026.07.362","url":"https://doi.org/10.1016/j.annonc.2026.07.362","title":"P101-6 Molecular subtypes of advanced pulmonary large cell neuroendocrine carcinoma treated with immune checkpoint inhibitors","date":"2026-11-01","lba":false,"refs":{"drugs":[],"trials":["nct06154538","nct05035745","nct06590246"],"targets":["pik3r5"],"cancers":["lung-lcnec","cervical-small-cell-neuroendocrine-carcinoma"],"technologies":["checkpoint-inhibitor"]}},{"doi":"10.1016/j.annonc.2026.07.372","url":"https://doi.org/10.1016/j.annonc.2026.07.372","title":"P108-11 HAIC combined with camrelizumab and apatinib for hepatocellular carcinoma with PVTT: a retrospective study","date":"2026-11-01","lba":false,"refs":{"drugs":["camrelizumab-rivoceranib","camrelizumab","rivoceranib"],"trials":[],"targets":[],"cancers":["hcc"],"technologies":[]}},{"doi":"10.1016/j.annonc.2026.07.371","url":"https://doi.org/10.1016/j.annonc.2026.07.371","title":"P108-6 HAIC combined with TACE, camrelizumab, and apatinib for hepatocellular carcinoma with PVTT: a retrospective study","date":"2026-11-01","lba":false,"refs":{"drugs":["camrelizumab-rivoceranib","camrelizumab","rivoceranib"],"trials":[],"targets":[],"cancers":["hcc"],"technologies":[]}},{"doi":"10.1016/j.annonc.2026.07.387","url":"https://doi.org/10.1016/j.annonc.2026.07.387","title":"P114-3 JAVEMACS chart review of avelumab maintenance in advanced urothelial carcinoma in Japan: analysis in older patients","date":"2026-11-01","lba":false,"refs":{"drugs":["avelumab"],"trials":["nct05035745","nct06590246"],"targets":[],"cancers":["urethral-urothelial-carcinoma"],"technologies":[]}},{"doi":"10.1016/j.annonc.2026.07.391","url":"https://doi.org/10.1016/j.annonc.2026.07.391","title":"P117-8 Real-world data on neoadjuvant treatment in urothelial carcinoma: MVAC vs platinum doublet","date":"2026-11-01","lba":false,"refs":{"drugs":["platinum-etoposide"],"trials":["nct05562297","nct07412613"],"targets":[],"cancers":["urethral-urothelial-carcinoma"],"technologies":[]}},{"doi":"10.1016/j.annonc.2026.09.004","url":"https://doi.org/10.1016/j.annonc.2026.09.004","title":"TIGIT at a crossroads: lessons from SKYSCRAPER-03 in unresectable stage III NSCLC","date":"2026-09-01","lba":false,"refs":{"drugs":[],"trials":["nct06745882","nct07728955","nct06441344"],"targets":["tigit"],"cancers":["nsclc"],"technologies":[]}},{"doi":"10.1016/j.annonc.2026.09.006","url":"https://doi.org/10.1016/j.annonc.2026.09.006","title":"Adjuvant olaparib in germline BRCA carriers: new certainties and remaining open questions from the updated OlympiA results","date":"2026-09-01","lba":false,"refs":{"drugs":["olaparib"],"trials":["olympia"],"targets":[],"cancers":[],"technologies":[]}},{"doi":"10.1016/j.annonc.2026.09.013","url":"https://doi.org/10.1016/j.annonc.2026.09.013","title":"Corrigendum to “Ovarian reserve as a measure of adjuvant chemotherapy benefit in hormone receptor positive (HR-positive), HER2-negative, node-positive breast cancer in SWOG S1007 (RxPONDER)”","date":"2026-10-01","lba":false,"refs":{"drugs":[],"trials":["nct07381309","rxponder"],"targets":["her2"],"cancers":["breast-cancer","breast-hr-positive"],"technologies":[]}},{"doi":"10.1016/j.annonc.2026.09.014","url":"https://doi.org/10.1016/j.annonc.2026.09.014","title":"Efficacy of Cryotherapy in Preventing Taxane-Induced Neuropathy: The CryoPac Randomised Controlled Trial.","date":"2026-10-01","lba":false,"refs":{"drugs":[],"trials":["nct05281471","nct06463665"],"targets":[],"cancers":[],"technologies":[]}},{"doi":"10.1016/j.annonc.2026.07.211","url":"https://doi.org/10.1016/j.annonc.2026.07.211","title":"P001-1 Platelet-to-lymphocyte ratio and mean platelet volume predict cardiac risk in non-Hodgkin lymphoma with anthracyclines","date":"2026-11-01","lba":false,"refs":{"drugs":[],"trials":["jcog9801","nct07075328"],"targets":[],"cancers":["non-hodgkin-lymphoma","hodgkin-lymphoma","adult-t-cell-leukaemia-lymphoma"],"technologies":[]}},{"doi":"10.1016/j.annonc.2026.07.216","url":"https://doi.org/10.1016/j.annonc.2026.07.216","title":"P004-4 Demographics and survival of adult non-lymphoma lymphoid malignancies: 5-year study at an Indonesian Referral Hospital","date":"2026-11-01","lba":false,"refs":{"drugs":[],"trials":["jcog9801","nct07075328"],"targets":[],"cancers":["non-hodgkin-lymphoma","adult-t-cell-leukaemia-lymphoma"],"technologies":[]}},{"doi":"10.1016/j.annonc.2026.07.220","url":"https://doi.org/10.1016/j.annonc.2026.07.220","title":"P009-5 Combination of PARP Inhibitor and CDK4/6 Inhibitor in breast cancer: a systematic review of in vivo and in vitro studies","date":"2026-11-01","lba":false,"refs":{"drugs":[],"trials":["nct04862663","nct06790693"],"targets":["cdk4-6","parp"],"cancers":["breast-cancer"],"technologies":["cdk46-inhibitor"]}},{"doi":"10.1016/j.annonc.2026.07.232","url":"https://doi.org/10.1016/j.annonc.2026.07.232","title":"P018-3 Can neutrophil-lymphocyte ratio predict survival in neuroblastoma? Current perspective from a PRISMA based meta-analysis","date":"2026-11-01","lba":false,"refs":{"drugs":[],"trials":["nct07219576","precision-promise"],"targets":[],"cancers":["neuroblastoma"],"technologies":[]}},{"doi":"10.1016/j.annonc.2026.07.239","url":"https://doi.org/10.1016/j.annonc.2026.07.239","title":"P020-2 Dabrafenib for the treatment of melanoma: a meta-analysis of randomized clinical trials","date":"2026-11-01","lba":false,"refs":{"drugs":["dabrafenib-trametinib","dabrafenib"],"trials":[],"targets":[],"cancers":["melanoma"],"technologies":[]}},{"doi":"10.1016/j.annonc.2026.07.251","url":"https://doi.org/10.1016/j.annonc.2026.07.251","title":"P029-1 Advanced gallbladder neuroendocrine carcinoma with multiple metastases: a case report","date":"2026-11-01","lba":false,"refs":{"drugs":[],"trials":["nct05035745","nct06590246"],"targets":[],"cancers":["cervical-small-cell-neuroendocrine-carcinoma"],"technologies":[]}},{"doi":"10.1016/j.annonc.2026.07.252","url":"https://doi.org/10.1016/j.annonc.2026.07.252","title":"P029-7 B-cell lymphoma of female reproductive tract: a mind-boggling mystery of a boggy uterus","date":"2026-11-01","lba":false,"refs":{"drugs":[],"trials":["jcog9801","nct07075328"],"targets":["bcl10","bcl11b"],"cancers":["non-hodgkin-lymphoma","adult-t-cell-leukaemia-lymphoma"],"technologies":[]}},{"doi":"10.1016/j.annonc.2026.07.262","url":"https://doi.org/10.1016/j.annonc.2026.07.262","title":"P033-7 Impact of nasopharyngeal carcinoma (NPC) 3D spheroid size on PDT therapeutic efficacy: a pilot study","date":"2026-11-01","lba":false,"refs":{"drugs":[],"trials":["nct05281471","nct06463665"],"targets":[],"cancers":["nasopharyngeal"],"technologies":[]}},{"doi":"10.1016/j.annonc.2026.07.269","url":"https://doi.org/10.1016/j.annonc.2026.07.269","title":"P035-9 Ayurveda rasayana therapy (ART) helps reduce platinum-based chemotherapy induced fatigue: a retrospective chart review","date":"2026-11-01","lba":false,"refs":{"drugs":["platinum-etoposide"],"trials":["nct07381309"],"targets":[],"cancers":[],"technologies":[]}},{"doi":"10.1016/j.annonc.2026.07.281","url":"https://doi.org/10.1016/j.annonc.2026.07.281","title":"P046-1 Predictive modeling and potential biomarker exploration for neoadjuvant chemo-immunotherapy response in ESCC","date":"2026-11-01","lba":false,"refs":{"drugs":[],"trials":["nct05562297","nct07412613"],"targets":[],"cancers":["oesophageal-squamous-cell-carcinoma"],"technologies":[]}},{"doi":"10.1016/j.annonc.2026.07.292","url":"https://doi.org/10.1016/j.annonc.2026.07.292","title":"P054-8 5-Fluorouracil-induced hyperammonemia in a case of recurrent colon cancer","date":"2026-11-01","lba":false,"refs":{"drugs":["fluorouracil"],"trials":["nct06887218"],"targets":[],"cancers":["colon-cancer"],"technologies":[]}},{"doi":"10.1016/j.annonc.2026.07.299","url":"https://doi.org/10.1016/j.annonc.2026.07.299","title":"P060-3 A case of protein-losing enteropathy during zolbetuximab therapy in CLDN18.2-positive gastroesophageal junction cancer","date":"2026-11-01","lba":false,"refs":{"drugs":["zolbetuximab"],"trials":["nct04492488"],"targets":[],"cancers":[],"technologies":[]}},{"doi":"10.1016/j.annonc.2026.07.302","url":"https://doi.org/10.1016/j.annonc.2026.07.302","title":"P063-5 Conversion surgery following duodenal stent placement in unresectable advanced gastric cancer: a case report","date":"2026-11-01","lba":false,"refs":{"drugs":[],"trials":["nct05035745","nct06590246"],"targets":[],"cancers":["gastric"],"technologies":[]}},{"doi":"10.1016/j.annonc.2026.07.330","url":"https://doi.org/10.1016/j.annonc.2026.07.330","title":"P078-1 Lutein and 3'-epilutein as novel therapeutic agents for glioblastoma: preclinical evaluation of anti-tumor efficacy","date":"2026-11-01","lba":false,"refs":{"drugs":[],"trials":["nct05281471","nct06463665"],"targets":[],"cancers":["glioblastoma"],"technologies":[]}},{"doi":"10.1016/j.annonc.2026.07.335","url":"https://doi.org/10.1016/j.annonc.2026.07.335","title":"P082-3 Turning the tide: radiotherapy as salvage for refractory genital warts in an RVD patient","date":"2026-11-01","lba":false,"refs":{"drugs":[],"trials":["nct06949111","nct01827605"],"targets":["lats1"],"cancers":[],"technologies":[]}},{"doi":"10.1016/j.annonc.2026.07.352","url":"https://doi.org/10.1016/j.annonc.2026.07.352","title":"P096-2 Challenging presentation of Hodgkin lymphoma with overlapping life-threatening conditions: a case report","date":"2026-11-01","lba":false,"refs":{"drugs":[],"trials":["jcog9801","nct07075328"],"targets":[],"cancers":["hodgkin-lymphoma","non-hodgkin-lymphoma","adult-t-cell-leukaemia-lymphoma"],"technologies":[]}},{"doi":"10.1016/j.annonc.2026.07.374","url":"https://doi.org/10.1016/j.annonc.2026.07.374","title":"P109-7 Inflammatory ratios predict immune checkpoint inhibitor outcomes in first-line advanced hepatobiliary cancer","date":"2026-11-01","lba":false,"refs":{"drugs":[],"trials":["nct05035745","nct06590246"],"targets":[],"cancers":[],"technologies":[]}},{"doi":"10.1016/j.annonc.2026.07.375","url":"https://doi.org/10.1016/j.annonc.2026.07.375","title":"P109-8 Adebrelimab combined with transarterial chemoembolization for primary liver cancer: a retrospective study","date":"2026-11-01","lba":false,"refs":{"drugs":["adebrelimab"],"trials":["nct06475209"],"targets":[],"cancers":["hcc"],"technologies":[]}},{"doi":"10.1016/j.annonc.2026.07.379","url":"https://doi.org/10.1016/j.annonc.2026.07.379","title":"P111-6 Efficacy and safety of FGFR inhibitors in FGFR2 cholangiocarcinoma after prior therapy: a systematic review","date":"2026-11-01","lba":false,"refs":{"drugs":[],"trials":["nct05281471","nct06463665"],"targets":["fgfr2"],"cancers":[],"technologies":[]}},{"doi":"10.1016/j.annonc.2026.07.384","url":"https://doi.org/10.1016/j.annonc.2026.07.384","title":"P113-1 Impact of geriatric 8 score on survival of elderly patients with unresectable pancreatic cancer in first-line treatment","date":"2026-11-01","lba":false,"refs":{"drugs":[],"trials":["nct07539155","nct07353645"],"targets":[],"cancers":["pancreatic"],"technologies":[]}},{"doi":"10.1016/j.annonc.2026.09.003","url":"https://doi.org/10.1016/j.annonc.2026.09.003","title":"Is it time to reassess standard toxicity and patient-reported outcomes methodologies for the adjuvant use of immune checkpoint inhibitors (ICIs)?","date":"2026-09-01","lba":false,"refs":{"drugs":[],"trials":["nct06154538"],"targets":[],"cancers":[],"technologies":["checkpoint-inhibitor"]}},{"doi":"10.1016/j.annonc.2026.08.008","url":"https://doi.org/10.1016/j.annonc.2026.08.008","title":"Overall survival with abemaciclib in early breast cancer","date":"2026-09-01","lba":false,"refs":{"drugs":["abemaciclib"],"trials":[],"targets":[],"cancers":["breast-cancer"],"technologies":[]}},{"doi":"10.1016/j.annonc.2026.07.213","url":"https://doi.org/10.1016/j.annonc.2026.07.213","title":"P002-9 Expansion of CAR-T cell therapy applications and evolution of challenges in Japan: analysis from periodic surveys","date":"2026-11-01","lba":false,"refs":{"drugs":[],"trials":["nct04153734"],"targets":[],"cancers":[],"technologies":["car-t"]}},{"doi":"10.1016/j.annonc.2026.07.231","url":"https://doi.org/10.1016/j.annonc.2026.07.231","title":"P017-2 Proton beam therapy vs radiotherapy in pediatric medulloblastoma: a systematic review of survival and cognitive outcomes","date":"2026-11-01","lba":false,"refs":{"drugs":[],"trials":["nct06949111"],"targets":[],"cancers":["medulloblastoma"],"technologies":[]}},{"doi":"10.1016/j.annonc.2026.07.234","url":"https://doi.org/10.1016/j.annonc.2026.07.234","title":"P018-6 Cytoreduction with intra-arterial chemotherapy to facilitate surgical resection of choroid plexus tumors","date":"2026-11-01","lba":false,"refs":{"drugs":[],"trials":["nct07381309"],"targets":[],"cancers":[],"technologies":[]}},{"doi":"10.1016/j.annonc.2026.07.236","url":"https://doi.org/10.1016/j.annonc.2026.07.236","title":"P019-10 A case of primary gallbladder neuroendocrine carcinoma with extended survival following multimodal chemotherapy","date":"2026-11-01","lba":false,"refs":{"drugs":[],"trials":["nct07381309"],"targets":[],"cancers":["cervical-small-cell-neuroendocrine-carcinoma"],"technologies":[]}},{"doi":"10.1016/j.annonc.2026.07.284","url":"https://doi.org/10.1016/j.annonc.2026.07.284","title":"P047-7 Implementation of an antiemetic and infusion management protocol for zolbetuximab in a Medical Oncology Day Hospital","date":"2026-11-01","lba":false,"refs":{"drugs":["zolbetuximab"],"trials":[],"targets":[],"cancers":[],"technologies":[]}},{"doi":"10.1016/j.annonc.2026.07.287","url":"https://doi.org/10.1016/j.annonc.2026.07.287","title":"P051-3 Association of irAEs with survival in patients with unresectable gastric cancer treated with ICI-combined chemotherapy","date":"2026-11-01","lba":false,"refs":{"drugs":[],"trials":["nct07381309"],"targets":[],"cancers":["gastric"],"technologies":[]}},{"doi":"10.1016/j.annonc.2026.07.291","url":"https://doi.org/10.1016/j.annonc.2026.07.291","title":"P054-5 Travel distance, relative dose intensity, and survival in first-line chemotherapy for stage IV colorectal cancer","date":"2026-11-01","lba":false,"refs":{"drugs":[],"trials":["nct07381309"],"targets":[],"cancers":["colorectal"],"technologies":[]}},{"doi":"10.1016/j.annonc.2026.07.333","url":"https://doi.org/10.1016/j.annonc.2026.07.333","title":"P079-8 Establishment for institutional and multidisciplinary team approach for home-visiting injection chemotherapy","date":"2026-11-01","lba":false,"refs":{"drugs":[],"trials":["nct07381309"],"targets":[],"cancers":[],"technologies":[]}},{"doi":"10.1016/j.annonc.2026.07.347","url":"https://doi.org/10.1016/j.annonc.2026.07.347","title":"P092-2 An exploratory survey on quality of life impact of chemotherapy-induced nail disorders and needs for nail care products","date":"2026-11-01","lba":false,"refs":{"drugs":[],"trials":["nct07381309"],"targets":[],"cancers":[],"technologies":[]}},{"doi":"10.1016/j.annonc.2026.07.363","url":"https://doi.org/10.1016/j.annonc.2026.07.363","title":"P103-3 Rare presentations of neuromyelitis optica, breast & leptomeningeal metastases in EGFR-mutant lung cancer: a case report","date":"2026-11-01","lba":false,"refs":{"drugs":[],"trials":["nct07617805"],"targets":["egfr"],"cancers":["egfr-mutant-nsclc","lung-cancer"],"technologies":[]}},{"doi":"10.1016/j.annonc.2026.07.381","url":"https://doi.org/10.1016/j.annonc.2026.07.381","title":"P112-4 Exosomal osteopontin as a KRAS-RAB37-driven biomarker axis in pancreatic cancer","date":"2026-11-01","lba":false,"refs":{"drugs":[],"trials":["nct07353645"],"targets":["kras","psmd1"],"cancers":["pancreatic"],"technologies":["kras-inhibitors"]}},{"doi":"10.1016/j.annonc.2026.07.386","url":"https://doi.org/10.1016/j.annonc.2026.07.386","title":"P113-6 Immunometabolic interaction: lip reprogramming of macrophages in pancreatic cancer through EPH-ephrin repulsion","date":"2026-11-01","lba":false,"refs":{"drugs":[],"trials":["nct07353645"],"targets":[],"cancers":["pancreatic"],"technologies":[]}},{"doi":"10.1016/j.annonc.2026.07.392","url":"https://doi.org/10.1016/j.annonc.2026.07.392","title":"P118-4 A case study of five cases of therapy-related myelodysplastic syndromes following chemotherapy for gynecological cancer","date":"2026-11-01","lba":false,"refs":{"drugs":[],"trials":["nct07381309"],"targets":[],"cancers":["mds","cmml"],"technologies":[]}},{"doi":"10.1016/j.annonc.2026.07.393","url":"https://doi.org/10.1016/j.annonc.2026.07.393","title":"P118-8 Long-term recurrence-free survivors used olaparib for recurrent ovarian, fallopian tube, and primary peritoneal cancers","date":"2026-11-01","lba":false,"refs":{"drugs":["olaparib"],"trials":[],"targets":[],"cancers":[],"technologies":[]}},{"doi":"10.1016/j.annonc.2026.07.402","url":"https://doi.org/10.1016/j.annonc.2026.07.402","title":"P125-2 Olanzapine for the prevention and treatment of chemotherapy-induced nausea and vomiting","date":"2026-11-01","lba":false,"refs":{"drugs":[],"trials":["nct07381309"],"targets":[],"cancers":[],"technologies":[]}}],"errors":[]}